Download PDF
Thromb Haemost 1986; 55(01): 065-069
DOI: 10.1055/s-0038-1661449
Original Article
Schattauer GmbH Stuttgart

The Fast-Acting Inhibitor of Tissue-Type Plasminogen Activator in Plasma Is also the Primary Plasma Inhibitor of Urokinase

Egbert K.O Kruithof
The Hematology Division, Department of Medicine, University Hospital Center, CHUV, Lausanne, Switzerland
,
Chiên Tran-Thang
The Hematology Division, Department of Medicine, University Hospital Center, CHUV, Lausanne, Switzerland
,
Fedor Bachmann
The Hematology Division, Department of Medicine, University Hospital Center, CHUV, Lausanne, Switzerland
› Author Affiliations
Further Information

Publication History

Received 09 August 1985

Accepted 31 October 1985

Publication Date:
19 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

We have compared the ability of a plasminogen activator inhibitor (PA-inhibitor) in human plasma, to form complexes with radioiodinated tissue-type plasminogen activator (t-PA) and high molecular weight urokinase (HMr-UK). Addition of 125I-t-PA (final concentration 10 IU/ml) or of 125I-HMr-UK (2 IU/ml) to a plasma containing 33 U/ml of PA-inhibitor resulted in the rapid formation of a 110,000 Mr complex of 125I-t-PA or a 95,000 Mr complex of 125I-HMr-UK with PA-inhibitor. Upon prolonged incubation of the plasma with 125I-HMr-UK a secondary complex of a Mr of 88,000 was observed, which probably derives from limited degradation of the 95,000 complex. Preincubation of the plasma with unlabelled t-PA, HMr-UK or LMr-UK at higher concentrations prevented the subsequent formation of complexes between radiolabelled PAs and the PA-inhibitor. These results thus demonstrate that t-PA and UK form complexes with the same PA-inhibitor. The rate of complex formation of 125I-t-PA or of 125I-HMr-UK with the plasma PA-inhibitor was similar (second order rate constant of association with PA-inhibitor in the order of 107 M−1s−1).

Key words

Plasminogen activator inhibitor - Tissue-type plasminogen activator - Urokinase - PA-inhibitor, t-PA, UK
 

  • References

  • 1 Rijken DC, Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815-830
    CrossrefPubMedSearch in Google Scholar
  • 2 Holmberg L, Nilsson IM, Wallén P, Åstedt B. Studies of the blood plasminogen activator induced by l-desamino-8-D-arginine vasopressin with observations in von Willebrand’s disease. Proc Soc Exp Biol Med 1982; 170: 126-132
    CrossrefPubMedSearch in Google Scholar
  • 3 Wun TC, Schleuning WD, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem 1982; 257: 3276-3283
    PubMedSearch in Google Scholar
  • 4 Tissot JD, Schneider Ph, Hauert J, Ruegg M, Kruithof EKO, Bachmann F. Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase. J Clin Invest 1982; 70: 1320-1323
    CrossrefPubMedSearch in Google Scholar
  • 1 Kruithof EKO, Ransijn A, Bachmann F. Inhibition of tissue plasminogen activator by human plasma. In "Progress in Fibrinolysis". Davidson JF, Bachmann F, Bouvier CA, Kruithof EKO. (Eds) Churchill Livingstone; Edinburgh: 1983. 06 365-369
    Search in Google Scholar
  • 6 Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
    PubMedSearch in Google Scholar
  • 7 Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436
    CrossrefPubMedSearch in Google Scholar
  • 8 Juhan-Vague I, Moerman B, De Cock F, Aillaud MF, Collen D. Plasma levels of k specific inhibitor of tissue-type plasminogen activator(and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-530
    CrossrefPubMedSearch in Google Scholar
  • 9 Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
    PubMedSearch in Google Scholar
  • 10 Wiman B, Chmielewska J, Ranby M. Inactivation of tissue plasminogen activator in plasma. J Biol Chem 1984; 259: 3644-3647
    PubMedSearch in Google Scholar
  • 11 Kruithof EKO, Gudinchet A, Tran-Thang C, Ransijn A, Bachmann F. Antiactivator levels in various disease states. In "Progress in Fibrinolysis". Davidson JF, Coccheri S, Donati MB. (Eds) Churchill Livingstone; Edinburgh: 1985. 7 130-132
    Search in Google Scholar
  • 12 Huber K, Kirchheimer J, Binder BR. Characterization of a specific anti-human urokinase antibody: development of a sensitive competition radioimmunoassay for urokinase antigen. J Lab Clin Med 1984; 103: 684-694
    PubMedSearch in Google Scholar
  • 13 Wun TC, Ossowski L, Reich E. A proenzyme form of human urokinase. J Biol Chem 1982; 257: 7262-7268
    PubMedSearch in Google Scholar
  • 14 Kluft C, Wijngaards G, Jie AFH. Intrinsic plasma fibrinolysis: involvement of urokinase-related activity in the factor XII independent plasminogen proactivator pathway. J Lab Clin Med 1984; 103: 408-419
    PubMedSearch in Google Scholar
  • 15 Kruithof EKO, Schleuning WD, Bachmann F. Human tissue-type plasminogen activator. Production in continuous serum-free cell culture and rapid purification. Biochem J 1985; 226: 631-636
    CrossrefPubMedSearch in Google Scholar
  • 16 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
    CrossrefPubMedSearch in Google Scholar
  • 17 Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloramide, 1, 3, 4, 6-tetrachloro-3a-6a-diphenyl glycoluril. Biochem Biophys Res Commun 1978; 80: 849-857
    CrossrefPubMedSearch in Google Scholar
  • 18 Kruithof EKO, Ransijn A, Bachmann F. Influence of detergents on the measurement of the fibrinolytic activity of plasminogen activators. Thromb Res 1982; 28: 251-260
    CrossrefPubMedSearch in Google Scholar
  • 19 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedSearch in Google Scholar
  • 20 Murano F, Aronson D, Williams L, Brown L. The inhibition of high and low molecular weight urokinase in plasma. Blood 1980; 55: 430-436
    PubMedSearch in Google Scholar
  • 21 Waller EK, Schleuning WD, Reich E. Complex formation and inhibition of urokinase by blood plasma proteins. Biochem J 1983; 215: 123-131
    CrossrefPubMedSearch in Google Scholar
  • 22 Holmberg L, Lecander I, Astedt B. Binding of urokinase to plasma proteinase inhibitors. Scand J Clin Lab Invest 1980; 40: 743-747
    CrossrefPubMedSearch in Google Scholar
  • 23 Travis J, Salvesen GS. Human plasma proteinase inhibitors. Ann Rev Biochem 1983; 52: 655-709
    CrossrefPubMedSearch in Google Scholar
  • 24 Kawano T, Morimoto K, Uemura Y. Partial purification and properties of urokinase inhibitor from human placenta. J Biochem 1970; 67: 333-342
    CrossrefPubMedSearch in Google Scholar
  • 25 Christensen U, Holmberg L, Bladh B, Åstedt B. Kinetics of the reaction between urokinase and an inhibitor of fibrinolysis from placental tissue. Thromb Haemostas 1982; 48: 24-26
    PubMedSearch in Google Scholar
  • 26 Scott RW, Eaton DL, Duran N, Baker JB. Regulation of extracellular plasminogen activator by human fibroblasts. The role of protease nexin. J Biol Chem 1983; 258: 4397-4403
    PubMedSearch in Google Scholar
  • 27 Crutchley DJ, Conanan LB, Maynard JR. Human fibroblasts produce inhibitor directed against plasminogen activator when treated with glucocorticoids. Ann N Y Acad Sci 1981; 370: 609-616
    CrossrefPubMedSearch in Google Scholar
  • 28 Loskutoff DJ, Van Mourik JA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 1983; 80: 2956-2960
    CrossrefPubMedSearch in Google Scholar
  • 29 Esnard F, Dupuy E, Dosne AM, Bodevin E. Partial characterization of a fibrinolytic inhibitor produced by cultured endothelial cells derived from human umbilical veins. Thromb Haemostas 1982; 47: 128-31
    PubMedSearch in Google Scholar
  • 30 Coleman PL, Barouski PA, Gelehrter TD. The dexamethasone-induced inhibitor of fibrinolytic activity in hepatoma cells. J Biol Chem 1982; 257: 4260-4264
    PubMedSearch in Google Scholar
  • 31 Golder JP, Stephens RW. Minactivin: a human monocyte product which specifically inactivates urokinase-type plasminogen activators. Eur J Biochem 1983; 136: 517-522
    CrossrefPubMedSearch in Google Scholar
  • 32 Chapman HA, Vavrin Z, Hibbs JB. Macrophage fibrinolytic activity: identification of two pathways of plasmin formation by intact cells and of a plasminogen activator inhibitor. Cell 1982; 28: 653-662
    CrossrefPubMedSearch in Google Scholar
  • 33 Vassalli JD, Dayer JM, Wohlwend A, Belin D. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med 1984; 159: 1653-1668
    CrossrefPubMedSearch in Google Scholar
  • 34 Lecander I, Roblin R, Åstedt B. Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor. Br J Haematol 1984; 57: 407-412
    CrossrefPubMedSearch in Google Scholar
  • 35 Travis J, Johnson D. The carboxy terminal sequence of human ar proteinase inhibitor. Biochem Biophys Res Commun 1978; 84: 219-224
    CrossrefPubMedSearch in Google Scholar
  • 36 Jörnvall H, Fish WW, Björk I. The thrombin cleavage site in bovine antithrombin. FEBS Letters 1979; 106: 358-362
    CrossrefPubMedSearch in Google Scholar
  • 37 Wiman B, Collen D. On the mechanism of the reaction between human α2-antiplasmin and plasmin. J Biol Chem 1979; 254: 9291-9297
    PubMedSearch in Google Scholar